智飞生物：截至目前，宸安生物有1款产品已进入上市审评，多款产品处于临床试验阶段

Group 1 - The core viewpoint of the article highlights that Zhifei Biological (300122.SZ) has one product under review for market launch and multiple products in clinical trials, indicating ongoing development and potential future offerings [1] - An investor inquiry on the interactive platform noted that major pharmaceutical companies Novo Nordisk and Eli Lilly have significantly exceeded performance expectations, with 85% of their sales coming from the Chinese market, raising questions about Zhifei Biological's ability to regain market share and improve its performance once its products are launched [3]